Inflammation plays an important role in pathogenesis, development and progression of lung cancer. Widespread literature exists on the prognostic impact of tumor-related factors, whereas host-related factors have not been deeply evaluated to date. Inflammatory indicators could play a vital role in assisting Medical Oncologists to identify which patients are considered at a higher probability of unfavourable prognosis and probably worse toxicity, justifying an appropriate management plan in advance.

In this podcast Stephen Clarke, Professor of Medicine from the University of Sydney joins Associate Professor Kellie Charles, Head of Pharmacology at the University of Sydney Australia, who were part of the team that discovered that cancer-related inflammation altered chemotherapy pharmacokinetics, toxicity and survival, to discuss the issue.

Thank you to Novartis for sponsoring this Podcast.